Novartis Increases Stake in Alnylam

Alnylam Pharmaceuticals (NASDAQ: ALNY), a Cambridge, MA, biotech firm working on RNAi-based therapies, said today that pharmaceutical giant Novartis had exercised an option to purchase approximately $5.4 million worth of Alnylam’s unregistered shares (i.e. restricted shares that were never offered for sale on the public market). The purchase boosts Novartis’s ownership stake in Alnylam slightly, from 13 percent to 13.4 percent.

Wade Roush is a freelance science and technology journalist and the producer and host of the podcast Soonish. Follow @soonishpodcast

Trending on Xconomy